drug

ML-007C-MA

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by MapLight Therapeutics
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647Phase 2Recruiting
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660Phase 2Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192Phase 2Recruiting

KOLs & investigators

1
MapLight Therapeutics

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
MapLight Therapeutics
company
trial
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
PHASE2
trial
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
PHASE2
trial
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
PHASE2
trial
indication
Schizophrenia
indication
Central Nervous System Diseases
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Mental Disorders
indication
KOL
MapLight Therapeutics
KOL score —
person